Platinum-based adjuvant chemotherapy modulated PD-L1 expression, CD8+ TIL density and tumor mutation burden (TMB) in NSCLC patients (Sakai et al., 2019). The gene discussed is CD274; the disease is non-small cell lung carcinoma.